Biweekly Vinorelbine and Gemcitabine as Second-Line Treatment and Beyond in Non-Small Cell Lung Cancer

Publisher： Karger

E-ISSN： 1421-9794|56|5|353-358

ISSN： 0009-3157

Source： Chemotherapy, Vol.56, Iss.5, 2010-10, pp. : 353-358

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemcitabine Plus Vinorelbine as the Second-Line Treatment and Beyond in Elderly Patients with Platinum-Pretreated Advanced Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 60, Iss. 4, 2015-04 ,pp. : 267-273

Karger

Access to resources Recommend Favorite

A Randomized Phase II Trial of Gemcitabine plus Carboplatin: Biweekly versus Standard Schedules in Patients with Advanced Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 59, Iss. 5, 2014-05 ,pp. : 346-353

Karger

Access to resources Recommend Favorite

A Cost-Effectiveness Analysis of Docetaxel versus Pemetrexed in Second-Line Chemotherapy for Stage IIIb or IV Non-Small Cell Lung Cancer in China

By  

Chemotherapy, Vol. 56, Iss. 6, 2010-11 ,pp. : 472-477

Karger

Access to resources Recommend Favorite

A Phase II Study of First-Line Chemotherapy with Weekly Carboplatin Plus Gemcitabine in Advanced Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 58, Iss. 1, 2012-02 ,pp. : 78-83

Karger

Access to resources Recommend Favorite

Phase II Trial of Biweekly Chemotherapy with Docetaxel and Cisplatin in High-Risk Patients with Unresectable Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 59, Iss. 3, 2013-10 ,pp. : 159-166

Karger

Access to resources Recommend Favorite